Darling Ingredients reports Q1 2026 results on Monday against a backdrop of the most concentrated analyst upgrades the stock has seen in months — and the market is holding its breath on whether the numbers confirm the optimism.
The Street has turned decisively bullish in the run-up. Every recent analyst action has been a target-price raise, with no downgrades or hold initiations in the recent period. Jefferies lifted its target to $75 just this week; TD Cowen went to $76; UBS pushed all the way to $78 back in April. JPMorgan, Baird, Scotiabank, and Stephens all joined the chorus of higher targets over the past five weeks. The consensus mean now sits at $75.92 — a gap of more than 22% above DAR's current price of $62.27. The forward EPS momentum score ranks in the 100th percentile, and the 12-month forward EPS year-on-year increase ranks in the 90th percentile, meaning estimates have been climbing sharply and consistently heading into this print.
The bull case rests on the company's diversified exposure to renewable fuel feedstocks and the recovery in its Diamond Green Diesel joint venture margins, with analysts pointing to improving commodity tailwinds and regulatory clarity on biofuel blending mandates. The bear case is simpler: the stock has already climbed roughly 80% year-to-date, the PE multiple has compressed nearly 4 points over the past month to around 13.4x as earnings estimates rose faster than price, and EV/EBITDA has contracted about 1.5 turns over the same period — suggesting the market has already priced in a meaningful portion of the recovery. The analyst-recommendation divergence score ranks in only the 10th percentile, flagging that consensus has converged so tightly that any surprise, positive or negative, has limited cover.
Short positioning tells a quiet supporting story. Short interest has drifted up about 7% over the past month to 4.6% of the free float — noticeable, but far from extreme. The borrow market is relaxed: cost to borrow is well under 0.5% annually, and availability is wide, with the 52-week utilization peak at just 5.46%. Options are mildly defensive — the put/call ratio is running at 0.45, just a half standard deviation above its 20-day average — but nowhere near alarming. The ORTEX short score of 36 also sits in a moderate range. In aggregate, the lending and derivatives markets are not pointing to elevated fear; the more charged debate is happening entirely in the fundamental and valuation conversation.
The Q1 print will test whether Darling's actual quarterly results — expected around $1.55bn in revenue and $335m in EBITDA on consensus estimates — can validate the wave of analyst conviction that has pushed targets north of $75 while the stock still trades in the low $60s.
See the live data behind this article on ORTEX.
Open DAR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
